Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I first-in-human dose-escalation study of BI 764532 in DLL3-positive small cell lung carcinoma and other neuroendocrine neoplasms
jRCT2031260032Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of obrixtamig in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine carcinoma (NEC) and 1 more (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose and Number of patients with dose-limiting toxicities. Started Jan 2024; status: active, not recruiting.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine carcinoma (NEC)small cell carcinoma (SCC)
Beyond the preview
Go deeper on jRCT2031260032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260032.